ArticleDrug design, development and therapy2016
Fungistatic activity of all-trans retinoic acid against Aspergillus fumigatus and Candida albicans.
Article in Drug design, development and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Potential Antifungal Activity of Retinoids Against Non-Microorganisms · 2026Article
- Chronic Hyperplastic Candidiasis-An Adverse Event of Secukinumab in the Oral Cavity: A Case Report and Literature Review.Diseases (Basel, Switzerland) · 2025Article
- Retinoids as Alternative Antifungal Agents AgainstMicroorganisms · 2025Article
- Vitamins for the Management of Nail Disease: A Literature Review.Skin appendage disorders · 2024Review
- Quorum Quenching with a Diffusible Signal Factor Analog inPathogens (Basel, Switzerland) · 2023Article
- The Interplay betweenMicroorganisms · 2023Review
- Potential Strategies to Control the Risk of Antifungal Resistance in Humans: A Comprehensive Review.Antibiotics (Basel, Switzerland) · 2023Review
- All-Trans Retinoic Acid Effect onJournal of fungi (Basel, Switzerland) · 2022Article
- The Multifaceted Role of Mating Type of the Fungus and Sex of the Host in Studies of Fungal Infections in Humans.Journal of fungi (Basel, Switzerland) · 2022Review
- OralDiagnostics (Basel, Switzerland) · 2021Article
- Trifarotene: A Current Review and Perspectives in Dermatology.Biomedicines · 2021Review
- Antifungal Effect of All-Antimicrobial agents and chemotherapy · 2021Article
- Overall Prevalence and Prevalence Compared among Psoriasis Treatments of Onychomycosis in Patients with Nail Psoriasis and Fungal Involvement.BioMed research international · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFungal infections are a major complication in hematologic and neoplastic patients causing severe morbidity and mortality. Aspergillus fumigatus and Candida albicans are among the most invasive opportunistic pathogens in immunocompromised patients, and classic antifungal drugs are frequently unsuccessful in these patients. Recent reports hypothesize that the antifungal efficacy of all-trans retinoic acid (ATRA) is mainly related to its strong capacity to stimulate monocyte-mediated immunity, but no consideration was given to its potential direct fungistatic activity. Moreover, ATRA offers the opportunity for systemic therapy. METHODS AND
resultsWe investigated the efficacy of ATRA at different concentrations for its antifungal activity against opportunistic A. fumigatus and C. albicans obtained from clinical samples according to standard protocols. A fungistatic activity of ATRA on A. fumigatus and C. albicans at 0.5-1 mM concentration was documented up to 7 days.
conclusionThis is the first evidence of a direct and strong fungistatic activity of ATRA against A. fumigatus and C. albicans. The potential adjuvant therapeutic application of ATRA might be useful in the treatment and/or prevention of systemic mycoses in immunocompromised patients. The discovery of a direct fungistatic activity, in association with its reported immunomodulatory properties, makes ATRA an excellent candidate for new combined antifungal strategies for systemic mycoses in immunocompromised and cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.